---
figid: PMC6152498__kccy-17-15-1502567-g002
figlink: /pmc/articles/PMC6152498/figure/F0002/
number: F2
caption: Targeting the cell cycle in breast cancer. (a) Cell cycle vulnerabilities
  of HR+ breast tumours. The Rb/E2F/CDK4/6 pathway is generally competent in HR+ breast
  cancers, making these cells dependent on CDK4/6 for progression through the restriction
  point. In such cells with intact Rb, CDK4/6 inhibitors induce cell cycle arrest
  in G0/G1. (b) Potential mechanisms of resistance to CDK4/6 inhibitors in HR+ breast
  cancers. To overcome resistance to CDK4/6 inhibition, cells acquire molecular alterations
  that enable them to bypass the restriction point and uncouple their dependency on
  CDK4/6 activity for cell cycle progression. (c) Cell cycle vulnerabilities of TNBC
  tumours. TNBC tumours are typically TP53 mutant, highly aneuploid, and often exhibit
  centrosome amplification. These features make TNBC cells susceptible to the induction
  of further, intolerable, aneuploidy and multipolar spindle formation. TTK and PLK4
  inhibitors potentiate genomic instability and chromosome segregation errors in mitosis
  leading to cell death. (d) Potential mechanisms of resistance to TTK inhibition
  in TNBC. Gatekeeper mutations in TTK and delay of mitotic exit through impaired
  function of the APC/C have been demonstrated to confer resistance to TTK targeting
  drugs. Blue arrows/type indicate DNA amplification or activating mutations. Dashed
  lines indicate loss of activity/function. * indicates a gatekeeper mutation. Cell
  cycle checkpoints are indicated in red.
pmcid: PMC6152498
papertitle: 'Targeting the cell cycle in breast cancer: towards the next phase.'
reftext: KL Thu, et al. Cell Cycle. 2018;17(15):1871-1885.
pmc_ranked_result_index: '21464'
pathway_score: 0.7811381
filename: kccy-17-15-1502567-g002.jpg
figtitle: Targeting the cell cycle in breast cancer
year: '2018'
organisms: Homo sapiens
ndex: a1fea9c6-df15-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6152498__kccy-17-15-1502567-g002.html
  '@type': Dataset
  description: Targeting the cell cycle in breast cancer. (a) Cell cycle vulnerabilities
    of HR+ breast tumours. The Rb/E2F/CDK4/6 pathway is generally competent in HR+ breast
    cancers, making these cells dependent on CDK4/6 for progression through the restriction
    point. In such cells with intact Rb, CDK4/6 inhibitors induce cell cycle arrest
    in G0/G1. (b) Potential mechanisms of resistance to CDK4/6 inhibitors in HR+ breast
    cancers. To overcome resistance to CDK4/6 inhibition, cells acquire molecular
    alterations that enable them to bypass the restriction point and uncouple their
    dependency on CDK4/6 activity for cell cycle progression. (c) Cell cycle vulnerabilities
    of TNBC tumours. TNBC tumours are typically TP53 mutant, highly aneuploid, and
    often exhibit centrosome amplification. These features make TNBC cells susceptible
    to the induction of further, intolerable, aneuploidy and multipolar spindle formation.
    TTK and PLK4 inhibitors potentiate genomic instability and chromosome segregation
    errors in mitosis leading to cell death. (d) Potential mechanisms of resistance
    to TTK inhibition in TNBC. Gatekeeper mutations in TTK and delay of mitotic exit
    through impaired function of the APC/C have been demonstrated to confer resistance
    to TTK targeting drugs. Blue arrows/type indicate DNA amplification or activating
    mutations. Dashed lines indicate loss of activity/function. * indicates a gatekeeper
    mutation. Cell cycle checkpoints are indicated in red.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - APC
  - CDK1
  - E2F8
  - E2F7
  - E2F3
  - E2F6
  - FGFR1
  - FGFR2
  - CCND1
  - CCNE2
  - CCNE1
  - E2F2
  - E2F4
  - E2F5
  - E2F1
  - CDK4
  - CCNA1
  - CCNA2
  - PIK3R3
  - AKT3
  - AKT1
  - AKT2
  - MTOR
  - PIK3R5
  - PIK3R6
  - PIK3R4
  - CDK2
  - CDK6
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - MYC
  - PLK4
  - CCND2
  - CCND3
  - PIK3CA
  - ADCY10
  - TTK
  - Estrogen
  - APC
genes:
- word: APC/C
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: CDK1
  symbol: CDK1
  source: hgnc_symbol
  hgnc_symbol: CDK1
  entrez: '983'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: FGFR1/2
  symbol: FGFR1
  source: hgnc_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR1/2
  symbol: FGFR2
  source: hgnc_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: CyclinE
  symbol: Cyclin_E
  source: bioentities_symbol
  hgnc_symbol: CCNE2
  entrez: '9134'
- word: CyclinE
  symbol: Cyclin_E
  source: bioentities_symbol
  hgnc_symbol: CCNE1
  entrez: '898'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: CDK4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: CyclinA
  symbol: Cyclin_A
  source: bioentities_symbol
  hgnc_symbol: CCNA1
  entrez: '8900'
- word: CyclinA
  symbol: Cyclin_A
  source: bioentities_symbol
  hgnc_symbol: CCNA2
  entrez: '890'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AKT/MTOR
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT/MTOR
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT/MTOR
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT/MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: CDK2
  symbol: CDK2
  source: hgnc_symbol
  hgnc_symbol: CDK2
  entrez: '1017'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: Myc
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: PLK4
  symbol: PLK4
  source: hgnc_symbol
  hgnc_symbol: PLK4
  entrez: '10733'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND2
  entrez: '894'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND3
  entrez: '896'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: SAC
  symbol: SAC
  source: hgnc_alias_symbol
  hgnc_symbol: ADCY10
  entrez: '55811'
- word: TTK
  symbol: TTK
  source: hgnc_symbol
  hgnc_symbol: TTK
  entrez: '7272'
chemicals:
- word: Estrogen
  source: MESH
  identifier: D004967
diseases:
- word: APC
  source: MESH
  identifier: D011125
figid_alias: PMC6152498__F2
redirect_from: /figures/PMC6152498__F2
figtype: Figure
---
